These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35613488)

  • 41. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
    Hollander PA; Kushner P
    Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.
    Tricco AC; Antony J; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
    Syst Rev; 2013 Jun; 2():47. PubMed ID: 23810103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Yu M
    Front Endocrinol (Lausanne); 2022; 13():935039. PubMed ID: 36017316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Okitsu A; Asahina S
    Diabetes Obes Metab; 2016 Dec; 18(12):1207-1216. PubMed ID: 27436788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].
    Müller UA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):547. PubMed ID: 21351042
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
    Deacon CF
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():34-46. PubMed ID: 29364584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
    Janez A; Őrsy P; Stachlewska K; Salvesen-Sykes K; Billings LK; Philis-Tsimikas A
    Diabetes Obes Metab; 2020 Apr; 22(4):658-668. PubMed ID: 31858673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
    Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
    Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.